Alnylam Pharmaceuticals Inc. (ALNY)
Market Closed
24 Feb, 20:00
$
332. 85
+3.5
+1.06%
Pre Market
$
+0.35 +0.11% 333. 20
44.59B Market Cap
- P/E Ratio
- Div Yield
761,174 Volume
-3.56 Eps
$ 329.35
Previous Close Day Range
324.48 333.06
Year Range
205.87 495.55
Want to track ALNY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ALNY earnings report is expected in 63 days (29 Apr 2026)
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.
Investorplace | 1 year ago
Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200 range, while a failure could lead to a drop towards $100. The key question is whether HELIOS-B shows a meaningful efficacy benefit for Amvuttra versus a high bar established by rival compounds.
Seekingalpha | 1 year ago
